StockNow
Log in
U.S. Markets

Pfizer (PFE) reports positive Phase 2 results for its 25-valent pediatric pneumococcal vaccine candidate, showing robust immunogenicity, broader protection across 25 serotypes and enhanced serotype 3 responses versus PREVNAR 20

News detail

The candidate was well tolerated with no safety concerns. Pfizer has initiated its Phase 3 pediatric programme and advanced its adult programme to a 35-valent candidate.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)